Literature DB >> 16672440

Central venous catheter colonization by linezolid-resistant, vancomycin-susceptible Enterococcus faecalis.

Alexandre R Marra1, Yvette Major, Michael B Edmond.   

Abstract

Resistance to linezolid is rare in clinical isolates of Enterococcus faecalis. A strain resistant to this antimicrobial but susceptible to vancomycin was found to cause central venous catheter colonization in a patient who never received linezolid.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16672440      PMCID： PMC1479169          DOI： 10.1128/JCM.44.5.1915-1916.2006

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  11 in total

1.  Isolation of linezolid-resistant Enterococcus faecalis.

Authors:  T W Boo; R Hone; G Sheehan; M Walsh
Journal:  J Hosp Infect       Date:  2003-04       Impact factor: 3.926

Review 2.  Mechanisms of action of newer antibiotics for Gram-positive pathogens.

Authors:  Robert Ew Hancock
Journal:  Lancet Infect Dis       Date:  2005-04       Impact factor: 25.071

3.  Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.

Authors:  R D Gonzales; P C Schreckenberger; M B Graham; S Kelkar; K DenBesten; J P Quinn
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

4.  Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit.

Authors:  A P Johnson; L Tysall; M V Stockdale; N Woodford; M E Kaufmann; M Warner; D M Livermore; F Asboth; F J Allerberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-09-13       Impact factor: 3.267

5.  Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci.

Authors:  J Prystowsky; F Siddiqui; J Chosay; D L Shinabarger; J Millichap; L R Peterson; G A Noskin
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

6.  Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.

Authors:  R Leclercq; E Derlot; J Duval; P Courvalin
Journal:  N Engl J Med       Date:  1988-07-21       Impact factor: 91.245

7.  An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin.

Authors:  Kavindra V Singh; George M Weinstock; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.

Authors:  James E Ross; Tamara R Anderegg; Helio S Sader; Thomas R Fritsche; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2005-05       Impact factor: 2.803

Review 9.  Enterococcus faecalis resistant to linezolid: case series and review of the literature.

Authors:  Brian S Burleson; David J Ritchie; Scott T Micek; W Michael Dunne
Journal:  Pharmacotherapy       Date:  2004-09       Impact factor: 4.705

10.  Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.

Authors:  Mehmet Baysallar; Abdullah Kilic; Hakan Aydogan; Feriha Cilli; Levent Doganci
Journal:  Int J Antimicrob Agents       Date:  2004-05       Impact factor: 5.283
View more
  2 in total

1.  Detection of mutations conferring resistance to linezolid in Enterococcus spp. by fluorescence in situ hybridization.

Authors:  Guido Werner; Melanie Bartel; Nele Wellinghausen; Andreas Essig; Ingo Klare; Wolfgang Witte; Sven Poppert
Journal:  J Clin Microbiol       Date:  2007-05-02       Impact factor: 5.948

2.  Response to emerging infection leading to outbreak of linezolid-resistant enterococci.

Authors:  Marion A Kainer; Rose A Devasia; Timothy F Jones; Bryan P Simmons; Kelley Melton; Susan Chow; Joyce Broyles; Kelly L Moore; Allen S Craig; William Schaffner
Journal:  Emerg Infect Dis       Date:  2007-07       Impact factor: 6.883
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.